Literature DB >> 8862505

Cyproheptadine treatment in Cushing's disease.

R Tanakol1, F Alagöl, H Azizlerli, O Sandalci, T Terzioğlu, F Berker.   

Abstract

Cyproheptadine, a nonselective 5-hydroxytryptamine receptor blocking agent, reduces ACTH and beta-endorphin secretion from the ACTH-producing tumors. A 35-year-old female suffering from Cushing's disease due to microadenoma of the pituitary gland has been followed since the age of 15. Subtotal adrenalectomy followed by total adrenalectomy, pituitary irradiation, and transsphenoidal hypophysectomy, combined with second radiotherapy of the pituitary, were unsuccessful in achieving remission of the disease. Remission was achieved with cyproheptadine up to a dosage of 24 mg/day. Every attempt to discontinue cyproheptadine treatment was accompanied by recurrence of the disease. This is the first case of Cushing's disease in which cyproheptadine treatment has been the only efficacious therapy for a period of 11 yr. Cyproheptadine may be an alternative long-term therapy for Cushing's disease when other methods of treatment fail.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862505     DOI: 10.1007/BF03349875

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  A specific, non-chromatographic radioimmunoassay for human plasma cortisol.

Authors:  R J Dash; B G England; A R Midgley; G D Niswender
Journal:  Steroids       Date:  1975-11       Impact factor: 2.668

2.  Influence of thyroid hormone on estrogen metabolism in man.

Authors:  J FISHMAN; L HELLMAN; B ZUMOFF; T F GALLAGHER
Journal:  J Clin Endocrinol Metab       Date:  1962-04       Impact factor: 5.958

3.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

4.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.

Authors:  S W Lamberts; S A de Lange; S Z Stefanko
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

5.  Prolonged remission of a case of Cushing's disease following cessation of cyproheptadine therapy.

Authors:  M Wiesen; F Ross; D T Krieger
Journal:  Acta Endocrinol (Copenh)       Date:  1983-03

6.  Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.

Authors:  M E Quigley; K L Sheehan; R F Casper; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1980-05       Impact factor: 5.958

7.  Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation.

Authors:  J R Tucci; K J Nowakowski; I M Jackson
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

8.  Dynamics of adrenocorticotropin (ACTH) secretion in cyclic Cushing's syndrome: evidence for more than one abnormal ACTH biorhythm.

Authors:  R M Jordan; A Ramos-Gabatin; J W Kendall; D Gaudette; R C Walls
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

9.  Reduced frequency of pulsatile luteinizing hormone secretion in the luteal phase of the rhesus monkey. Involvement of endogenous opiates.

Authors:  D A Van Vugt; N Y Lam; M Ferin
Journal:  Endocrinology       Date:  1984-09       Impact factor: 4.736

10.  Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease.

Authors:  H P Koppeschaar; R J Croughs; J H Thijssen; F Schwarz
Journal:  Acta Endocrinol (Copenh)       Date:  1983-10
View more
  2 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  Pituitary-Directed Therapies for Cushing's Disease.

Authors:  Fabienne Langlois; Jennifer Chu; Maria Fleseriu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-01       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.